russia/ china vaccines have shortcomings

[3NUMBAS]

Scientists see downsides to top COVID-19 vaccines from Russia, China

Allison Martell and Julie Steenhuysen

,

Reuters•31 August 2020

 

By Allison Martell and Julie Steenhuysen

TORONTO/CHICAGO (Reuters) - High-profile COVID-19 vaccines developed in Russia and China share a potential shortcoming: They are based on a common cold virus that many people have been exposed to, potentially limiting their effectiveness, some experts say.

CanSino Biologics' vaccine, approved for military use in China, is a modified form of adenovirus type 5, or Ad5. The company is in talks to get emergency approval in several countries before completing large-scale trials, the Wall Street Journal reported last week.

A vaccine developed by Moscow's Gamaleya Institute, approved in Russia earlier this month despite limited testing, is based on Ad5 and a second less common adenovirus.

[dimitriv]

But at least they can say that they are first.

 

 

[Heppinger]

Russia has been conducting trials for years now.....